The listing below shows our latest News Items and is updated regularly. If you wish to post a news item please select the 'Post News' button on the right. The displayed news feed starts on 1st August 2016. Older items can be found here.
To 'Post Your News' use the button at the top right.
We are pleased to present below all posts archived in 'March, 2017'. If you still can't find what you are looking for, try using the search box.
Wickham Laboratories Ltd is pleased to announce that we will be on Stand 12 at the upcoming Med-Tech Innovation Expo, Ricoh Arena, Coventry, April 26-27.
Med-Tech Innovation Expo 2017 is the UK’s only dedicated medical device conference bringing together industry stakeholders and over 130 companies supplying services from design to post-market surveillance. Alongside the exhibition, there will be a centrepiece conference delivering insights and market intelligence via a wide range of expert speakers.
Read the rest of entry »
Tissue Solutions introduces additions to their extensive range of cellular products. Available immediately is their portfolio of human iPS-derived cell types which are conveniently already differentiated and ready to use.
British-Chinese three-way agreement brings together expertise and innovation in development of technologies for computational molecule design.
Oxford, UK Neuro-Bio Ltd, a UK-based early stage biopharmaceutical company focussingon neurodegenerative diseases, today announced it has received Series A funding of $3.2 million from US-based Kairos Ventures to continue developing a diagnostic tool for early detection of Alzheimer’s and to discover new drugs targeting the disease. Neuro-Bio has been pioneering a novel approach to Alzheimer’s disease and related neurodegenerative disorders since 2013. The innovative Neuro-Bio technology is the result of over 40 years of basic research by Baroness Professor Susan Greenfield's group, initially at Oxford University, that points to a previously unidentified mechanism underlying the continuing cycle of cell death that characterises the neurodegenerative process. The company has been exploring whether activation of this brain mechanism could be halted by pharmaceutical intervention and how these changes are reflected in a biomarker present in blood. The new investment will allow Neuro-Bio to develop the biomarker into a diagnostic tool and to make substantive progress towards identifying a lead compound with promising therapeutic potential in Alzheimer’s disease.
Elasmogen Ltd, developer of soloMERTM biologics, today announced that it has received a Biomedical Catalyst Grant from the UK’s innovation agency, Innovate UK and matching investment from Deepbridge Capital and Scottish Investment Bank (the investment arm of Scottish Enterprise) totalling £1.2 M. The funding will be used to develop ELN-21 and ELN-22, the companies’ next generation biologics for topical treatment of ocular disease.
Oxford, UK, 27 March 2017 - Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy ('DMD') and Clostridium difficile infection, announces that it will proceed with the planned extension phase of PhaseOut DMD, a Phase 2 clinical trial evaluating the utrophin modulator ezutromid, subject to regulatory approval. This follows an interim review of the safety and tolerability data from the ongoing trial by an independent Data Monitoring Committee ('DMC') and its support of Summit's plans to extend the clinical trial.
OXFORD, United Kingdom and MARLBOROUGH, Mass., March 23, 2017 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today announced the release of national T-SPOT®.TB test positivity rates within the United States and United Kingdom, as well as a grant to support TB screening for high risk patients.
Discussing the latest salary and market trends in the science industry, the report is based on over 3,000 responses from SRG’s global database and the readership of New Scientist magazine.
Oxford, UK - The Spring Budget delivered by the Chancellor on 8 March 2017 continues to hit the headlines. What is its potential impact on the UK biotech industry?
Wickham Laboratories Ltd will exhibit on Stand 309 at the Making Pharmaceuticals Conference on the 25th – 26th April 2017 at Ricoh Arena, Coventry.
OBN aims to provide sector NEWS that is relevant to our Membership. We filter information from a variety of sources, publish items ourselves and will publish items of News from our Members. Press releases about OBN can be found here.